Acrivon Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

ACRV$1.57-0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

	Common Stock
	Shares	Amount	AdditionalPaid-InCapital	AccumulatedOtherComprehensiveIncome (Loss)	AccumulatedDeficit	TotalStockholders’Equity
Balance at December 31, 2023	22,522,644	$23	$237,675	$(83)	$(116,420)	$121,195
Exercise of common stock options	20,277	—	79	—	—	79
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax	94,618	—	(166)	—	—	(166)
Stock-based compensation expense	—	—	3,344	—	—	3,344
Unrealized gain on available-for-sale investments, net of tax	—	—	—	13	—	13
Net loss	—	—	—	—	(16,486)	(16,486)
Balance at March 31, 2024	22,637,539	$23	$240,932	$(70)	$(132,906)	$107,979
Issuance of common stock in private placement, net of issuance costs of $3,360	8,235,000	8	66,629	—	—	66,637
Issuance of pre-funded warrants in private placement, net of issuance costs of $2,881	—	—	57,122	—	—	57,122
Exercise of common stock options	10,598	—	11	—	—	11
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax	83,118	—	(510)	—	—	(510)
Stock-based compensation expense	—	—	3,566	—	—	3,566
Unrealized gain on available-for-sale investments, net of tax	—	—	—	51	—	51
Net loss	—	—	—	—	(18,798)	(18,798)
Balance at June 30, 2024	30,966,255	$31	$367,750	$(19)	$(151,704)	$216,058
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax	164,637	—	(1,197)	—	—	(1,197)
Stock-based compensation expense	—	—	3,671	—	—	3,671
Unrealized gain on available-for-sale investments, net of tax	—	—	—	801	—	801
Net loss	—	—	—	—	(22,441)	(22,441)
Balance at September 30, 2024	31,130,892	$31	$370,224	$782	$(174,145)	$196,892

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share data)

	Common Stock
	Shares	Amount	AdditionalPaid-InCapital	AccumulatedOtherComprehensiveIncome (Loss)	AccumulatedDeficit	TotalStockholders’Equity
Balance at December 31, 2022	21,920,402	$22	$226,580	$(95)	$(56,032)	$170,475
Exercise of common stock options	232	—	—	—	—	—
Stock-based compensation expense	—	—	2,646	—	—	2,646
Unrealized gain on available-for-sale investments, net of tax	—	—	—	104	—	104
Net loss	—	—	—	—	(12,756)	(12,756)
Balance at March 31, 2023	21,920,634	$22	$229,226	$9	$(68,788)	$160,469
Exercise of common stock options	148,026	—	379	—	—	379
Stock-based compensation expense	—	—	2,686	—	—	2,686
Unrealized loss on available-for-sale investments, net of tax	—	—	—	(436)	—	(436)
Net loss	—	—	—	—	(13,914)	(13,914)
Balance at June 30, 2023	22,068,660	$22	$232,291	$(427)	$(82,702)	$149,184
Exercise of common stock options	35,669	—	78	—	—	78
Issuance of common stock upon vesting of restricted stock units	140	—	—	—	—	—
Stock-based compensation expense	—	—	3,228	—	—	3,228
Unrealized gain on available-for-sale investments, net of tax	—	—	—	125	—	125
Net loss	—	—	—	—	(14,466)	(14,466)
Balance at September 30, 2023	22,104,469	$22	$235,597	$(302)	$(97,168)	$138,149

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.